This post was originally published on this site A new study reports the development of compounds that could be used as ovarian cancer treatment. These compounds are particularly promising because they may be able to affect cancer that is resistant to chemotherapy. The study, “Exploring the Cytotoxicity, Uptake, Cellular Response, and Proteomics of Mono- and…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients
This post was originally published on this site CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed or refractory multiple myeloma, after the Chinese National Medical Products Administration (NMPA) cleared its investigational new drug (IND) application. In recent years, immunotherapy has gained…
Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer
This post was originally published on this site A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel (NCT03732820), the trial was recently presented at the 2019 Genitourinary Cancers Symposium, in San Francisco, in a poster…
Gamida Cell’s Therapy Shows Promise for Non-Hodgkin’s Lymphoma, Multiple Myeloma
This post was originally published on this site Gamida Cell’s natural killer cell treatment is a promising approach to treat adults with relapsed or refractory non-Hodgkin’s lymphoma or multiple myeloma, according to early data from an ongoing Phase 1 clinical trial. Data from the first 14 patients showed that the treatment was well-tolerated and eliminated cancer signs in…
Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals
This post was originally published on this site Immune checkpoint inhibitors may be safe and effective in advanced cancer patients with human immunodeficiency virus (HIV), according to a review study. The research, “Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review,” was published in JAMA Oncology. HIV-positive patients have a…
Subtypes of Immune Cells in Tumor Environment Can Predict Follicular Lymphoma Response to Therapy
This post was originally published on this site The presence of specific subtypes of immune cells in the tumor environment of people with follicular lymphoma can predict how a patient’s immune system will respond to the disease, as well as survival outcomes, a study shows. The study, “Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T…
Thousands of Lives Spared Thanks to Screening, Treatment, Study Reports
This post was originally published on this site Since 1989, between 384,000 and 615,000 women’s lives have been spared thanks to significant advancements in breast cancer screening methods and treatment, a study reports. The findings of the study, “Breast cancer deaths averted over 3 decades,” were published in Cancer. Statistics from the National Cancer Institute’s…
Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients
This post was originally published on this site Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), sponsored by Janssen, is testing 300 mg daily Zejula in patients whose disease worsened after treatment with…
Moral Dilemmas Complicate Treatment of Rare Diseases, Says Israeli Bioethicist
This post was originally published on this site With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,”…
Cell Medica Earns $8.7 Million Grant to Accelerate Off-the-shelf CAR-NKT Cell Therapy
This post was originally published on this site Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 million grant. In addition to being available “off-the-shelf,” the therapy — being developed in collaboration with the Baylor…
Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows
This post was originally published on this site Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in the FORWARD I Phase 3 trial. The treatment failed to extend survival without disease worsening in the…
Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says
This post was originally published on this site An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new formulation also led to similar levels of daratumumab in circulation, meeting the trial’s co-primary goals, according to Genmab, the…